Chimeric Antigen Receptor T Cell Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chimeric Antigen Receptor T Cell stocks.

Chimeric Antigen Receptor T Cell Stocks Recent News

Date Stock Title
May 20 NKTX Nkarta: A Promising Natural Killer Cell Play
May 20 JANX Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business
May 19 GRCL Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
May 19 CRBU Crispred CAR-T Cells In The Clinic
May 18 ACET Adicet Bio to Present at Upcoming Investor Conferences
May 18 NKTX What Makes Nkarta, Inc. (NKTX) a New Buy Stock
May 18 NKTX Can Nkarta, Inc. (NKTX) Climb 383% to Reach the Level Wall Street Analysts Expect?
May 18 PSTX Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors
May 17 CRBU Caribou Biosciences (CRBU) Investor Presentations - Slideshow
May 17 NTLA 10 Biggest Losers in Cathie Wood’s Latest Portfolio
May 17 PSTX Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting
May 16 CRBU Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells
May 16 NKTX Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
May 16 GRCL Gracell Biotechnologies Inc. (GRCL) CEO Dr. William Cao on Q1 2022 Results - Earnings Call Transcript
May 16 GRCL Gracell Biotechnologies GAAP EPS of -$0.07 in-line
May 16 GRCL Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update
May 16 GRCL Earnings Scheduled For May 16, 2022
May 15 PSTX Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15 ACET Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit